Developer docs
API playgroundTry for free, no card

Search company profiles

MedinCell

Full company profile

uuid0002a9f

Namestring
MedinCell
Legal namestring
MedinCell SA
Websiteurl
medincell.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

MedinCell SA is a clinical- and commercial-stage biopharmaceutical company headquartered near Montpellier, France, that develops long-acting injectable (LAI) drug formulations on its proprietary BEPO technology platform. BEPO uses PEG-PLA diblock and triblock copolymers that form a small, fully bioresorbable subcutaneous or local depot upon contact with aqueous environments; the depot releases the entrapped active pharmaceutical ingredient by diffusion and polymer degradation at therapeutic levels for days, weeks, or months from a single injection, with release kinetics tunable via the hydrophilicity and ratio of the diblock and triblock components. The platform underpins 15 active programs spanning neuroscience, immunology, oncology, endocrinology, infectious diseases, and pain management. The lead commercial product, UZEDY (risperidone LAI, marketed under the SteadyTeq trademark by Teva), received FDA approval in April 2023 for schizophrenia and was expanded in October 2025 to include Bipolar I Disorder, with additional approvals in Canada and South Korea in 2025.

MedinCell operates a licensing- and royalty-driven business model rather than direct commercialization. Its primary commercial partner is Teva Pharmaceuticals, which markets UZEDY in the United States, Canada, and South Korea and is co-developing olanzapine LAI (TEV-749/mdc-TJK), for which both FDA NDA acceptance (February 2026) and EMA MAA acceptance (May 2026) have been secured. The company also has a strategic co-development agreement with AbbVie for next-generation LAIs, a partnership with Arthritis Innovation Corporation for mdc-CWM (intra-articular celecoxib for post-operative pain), and non-dilutive grant funding from the Bill & Melinda Gates Foundation and Unitaid for global health programs targeting malaria (mdc-STM) and contraception (mdc-WWM). FY2026 total income was €24.3 million, with UZEDY royalties contributing €9.3 million (+42% year-over-year, now 38% of total revenue) and the company reporting a net loss of €31.29 million against a year-end cash position of €80.8 million, bolstered by a €48 million private placement completed in March 2026.

The company employs approximately 140 people across more than 25 nationalities, with 73% of staff dedicated to R&D and 91% participating as shareholders. MedinCell is publicly listed on Euronext Paris under the ticker MEDCL, was included in the MSCI World Small Cap Index effective November 24, 2025, and holds ISS ESG Prime Status with a Corporate Rating upgraded from C+ to B in 2025. The board and management team include veterans of Teva, Novartis, Alcon, AbbVie Ventures, and Intra Cellular Therapies, supporting the company's stated "Shift to Growth" strategy of transitioning toward a royalty-driven commercial model.

Short descriptiontext

MedinCell is a French clinical- and commercial-stage biopharmaceutical company that licenses its proprietary BEPO long-acting injectable polymer platform to pharmaceutical partners, generating royalties from Teva's UZEDY (risperidone LAI) and co-developing pipeline assets in schizophrenia, pain, contraception, and malaria.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting injectables, bioresorbable polymers, drug delivery systems, biopharmaceutical licensing, sustained-release formulations
Industry4 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Long-acting injectable pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Royalty Income from UZEDY
TypeLicensing Royalties
Description

MedinCell receives mid- to high-single-digit royalties on UZEDY net sales from Teva. UZEDY royalties reached EUR 9.3 million in FY2026, representing 38% of total revenue, up from 22% in FY2025. Teva's net sales of UZEDY reached $215 million in FY2026, up 52.5% year over year.

medincell.com
2Commercial Milestone Payments
TypeLicensing Royalties
Description

MedinCell is eligible for up to $105 million in commercial milestone payments upon achievement of annual sales thresholds for UZEDY. Additional $4 million payment upon approval for Olanzapine LAI.

medincell.com
3R&D Grants and Non-dilutive Funding
TypeLicensing Royalties
Description

Funding from foundations for global health programs: $19 million grant from Bill & Melinda Gates Foundation for mdc-WWM contraceptive program, up to $6.4 million from Unitaid for malaria program (mdc-STM), with extension grants of up to $6 million. $3 million grant from Gates Foundation for ivermectin-based malaria treatment (mdc-STM).

medincell.com
4Co-development and Licensing Agreements
TypeLicensing Royalties
Description

Strategic co-development and licensing partnerships including AbbVie collaboration for next-generation LAI therapies. Revenue from upfront payments, development milestones, and royalties from partnered programs.

medincell.com
5Private Placement and Equity Financing
TypeLicensing Royalties
Description

EUR 48 million private placement completed March 2026 through issuance of 2,370,000 new shares at EUR 20.35 per share. EUR 40 million loan agreement with European Investment Bank signed November 2022.

medincell.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Royalty-based revenue model from licensed products
ModelSubscriptionBilling cadenceAnnual
Notes

Mid- to high-single-digit royalties on UZEDY net sales. Up to $105 million in commercial milestone payments upon achievement of annual sales thresholds. $4 million payment upon approval of Olanzapine LAI.

businesswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1UZEDY
Description

Monthly and every 2 months subcutaneous risperidone for treatment of schizophrenia and Bipolar I Disorder; FDA-approved long-acting injectable based on BEPO technology, marketed by Teva in the US

medincell.com
+2 more records
Core offering1 text field

MedinCell develops and licenses its proprietary BEPO® long-acting injectable technology platform, which uses PEG-PLA diblock and triblock copolymers to form a small, fully bioresorbable depot under the skin that delivers active pharmaceutical ingredients at therapeutic levels for days, weeks, or months following a single subcutaneous or local injection. The commercial-stage product UZEDY® (risperidone long-acting injectable) is FDA-approved for schizophrenia and Bipolar I Disorder and is marketed by partner Teva. The company monetizes the technology through royalties, milestone payments, and co-development partnerships with leading pharmaceutical companies and global health foundations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • UZEDY net sales grew 63% from $117M in 2024 to $191M in 2025
+5 more records
Product overview1 text field

MedinCell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments. The portfolio centers on the proprietary BEPO® technology platform, which enables controlled drug delivery via bioresorbable depots. The commercial-stage product UZEDY® (risperidone LAI) is marketed by Teva for schizophrenia and Bipolar I Disorder. The pipeline includes mdc-TJK (olanzapine LAI, Phase 3 complete, NDA/MAA accepted), mdc-CWM (post-operative pain, Phase 3 complete), mdc-WWM (contraceptive, Phase 1), mdc-STM (malaria, preclinical), and mdc-AbbVie-1 (confidential, partnership with AbbVie). Programs span neuroscience, immunology, oncology, endocrinology, infectious diseases, and pain management. The company has 15 active programs total.

Product and service7 records
1UZEDY® (risperidone long-acting injectable)
CategoryCommercial-stage long-acting injectable product
Description

Monthly and every-two-months subcutaneous risperidone long-acting injectable based on BEPO® technology for the treatment of schizophrenia and Bipolar I Disorder in adults. FDA-approved in April 2023 for schizophrenia, with expanded indication for Bipolar I Disorder approved October 2025. Marketed by Teva in the US under the SteadyTeq® license and also approved in Canada (marketed as LONGAVO®) and South Korea in 2025.

2mdc-TJK (Olanzapine long-acting injectable)
CategoryPipeline product (Phase 3 complete, under regulatory review)
Description

Investigational once-monthly subcutaneous long-acting injection of olanzapine for treatment of schizophrenia, in partnership with Teva Pharmaceuticals. Phase 3 complete with SOLARIS trial data showing no PDSS (Postinjection Delirium/Sedation Syndrome) and no required post-injection monitoring, differentiating from existing olanzapine LAIs that carry FDA black box warnings and REMS requirements. NDA accepted by FDA in February 2026 and Marketing Authorization Application accepted by EMA in May 2026.

3mdc-CWM (intra-articular celecoxib)
CategoryPipeline product (Phase 3 complete)
Description

One-time intra-articular celecoxib sustained-release formulation for post-operative pain relief after total knee replacement surgery, active for up to three months post-surgery. Collaboration with Arthritis Innovation Corporation (AIC) based in Toronto, Canada, which finances and conducts clinical development. Phase 3 results positive, with the goal of reducing opioid dependency.

4mdc-WWM (6-month subcutaneous contraceptive)
CategoryPipeline product (Phase 1)
Description

Six-month active injectable bioresorbable subcutaneous contraceptive using a non-MPA progestin molecule. Could be the first contraceptive combining 6-month duration, subcutaneous injection, full bio-resorption, and affordability for women in low- and middle-income countries. Funded by up to $19 million grant from the Bill & Melinda Gates Foundation as part of MedinCell's Global Access strategy. Preclinical and Phase 1 activities ongoing.

5mdc-STM (3-month ivermectin for malaria)
CategoryPipeline product (preclinical)
Description

Three-month ivermectin long-acting injectable for malaria transmission control. Administered at the beginning of transmission season to eliminate malaria-transmitting mosquitoes. Collaboration with IRD, IRSS, and CIRDES research institutes. Supported by Unitaid (up to $6.4M initial grant plus up to $6M extension) and the Bill & Melinda Gates Foundation ($3M grant). Licensed non-exclusively to the Medicines Patent Pool for distribution via the public sector in low- and middle-income countries.

6mdc-AbbVie-1 (next-generation long-acting injectable)
CategoryPipeline product (preclinical / partnership program)
Description

Confidential next-generation long-acting injectable therapy program developed under strategic co-development and licensing agreement with AbbVie, signed April 2024. The collaboration represents MedinCell's expansion beyond neuroscience into other therapeutic areas; specific indication and molecule details are confidential. Clinical trials are expected to begin in 2027.

7BEPO® Technology Platform (licensed as SteadyTeq®)
CategoryTechnology platform (licensed to pharmaceutical partners)
Description

Proprietary long-acting injectable technology platform enabling controlled drug delivery at therapeutic levels for several days, weeks, or months following subcutaneous or local injection of a small, fully bioresorbable depot. Composed of PEG-PLA diblock and triblock copolymers that form an in-situ depot millimeters under the skin when exposed to aqueous environment. Licensed to Teva under the SteadyTeq® trademark and used in UZEDY® and TEV-749 olanzapine LAI products. The platform enables tunable release kinetics by adjusting copolymer hydrophilicity and relative ratio.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-16
Description

Strategic co-development and licensing agreement to develop next-generation long-acting injectable therapies. First clinical development program with AbbVie has been delayed, with trials now expected to begin in 2027. The collaboration represents MedinCell's expansion beyond neuroscience into other therapeutic areas.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-28
Description

Teva is the primary commercial partner for MedinCell's BEPO technology. Teva markets UZEDY (risperidone LAI) in the US, Canada, and South Korea following FDA approval in April 2023 and subsequent approvals. Teva is also co-developing olanzapine LAI (TEV-749/mdc-TJK) with MedinCell's SteadyTeq technology. Teva reported $191 million in UZEDY net sales in 2025 and $215 million in FY2026. MedinCell receives mid- to high-single-digit royalties on net sales.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2022-09-14
Description

License agreement for malaria transmission-fighting product distribution via public sector in low- and middle-income countries. Part of MedinCell's Global Access strategy to ensure equitable access to health products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-25
Description

$6.4 million initial grant and up to $6 million extension grant for mdc-STM, a 3-month ivermectin formulation to combat malaria transmission. MedinCell signs license agreement with Medicines Patent Pool for distribution via public sector in LMICs.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2019-09-18
Description

Collaboration for mdc-CWM, a one-time intra-articular celecoxib formulation for post-operative pain relief after total knee replacement. AIC finances and conducts clinical development activities. Phase 3 results have been positive.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-07
Description

Up to $19 million grant for development of mdc-WWM, a 6-month injectable bioresorbable subcutaneous contraceptive. The Global Access strategy aims to ensure widespread availability with affordable pricing in emerging economies. Foundation holds non-exclusive license for non-commercial market in low- and middle-income countries.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Teva is MedinCell's primary commercialization partner for UZEDY and olanzapine LAI. Teva provides commercial reach and infrastructure; they are not a peer in the technology sense but their commercial performance directly drives MedinCell's royalty stream.

TypeDirect peer
Description

Camurus is a Swedish specialty pharma with FluidCrystal technology for long-acting injectable and depot formulations. Markets Buvidal (buprenorphine LAI) for opioid use disorder. Closely comparable as a technology-platform LAI developer partnering with larger pharma.

TypeDirect peer
Description

Otsuka markets Abilify Maintena and Abilify Asimtufii (aripiprazole LAI) for schizophrenia. Direct competitor to UZEDY/risperidone LAI in the long-acting injectable antipsychotic space and comparable therapeutic-area presence.

TypeDirect peer
Description

Alkermes is a leading long-acting injectable technology company developing Vivitrol (naltrexone), Aristada (aripiprazole LAI), and Lybalvi. Directly comparable to MedinCell as a specialty pharma using proprietary depot technology to enable sustained-release injectables for CNS and addiction.

TypeDirect peer
Description

Developed Caplyta (lumateperone) for schizophrenia and bipolar, with a focus on CNS specialty pharma. Acquired by J&J in April 2025 for $14.6B. Comparable business model as a CNS-focused specialty pharma with innovative oral therapeutics for the same patient population.

TypeDirect peer
Description

Indivior is a specialty pharma focused on addiction treatment with Sublocade (buprenorphine LAI). Comparable as a single-indication LAI specialist that built a commercial-stage franchise around sustained-release depot technology.

TypeOthers
Description

PolyPeptide is a CDMO specializing in peptide-based and sustained-release injectable formulations. Not a direct competitor but adjacent infrastructure provider in the LAI/depot formulation ecosystem that MedinCell operates within.

TypeRegional player
Description

Luye Pharma developed a risperidone long-acting injectable (Rykindo) approved in the US and operates a microsphere-based LAI platform. Comparable as a global LAI developer; primary geographic focus on China and Asia.

TypeEmerging player
Description

Heron Therapeutics developed sustained-release postoperative pain management products using its Biochronomer polymer technology. Comparable as a specialty pharma using polymer-based LAI/depot technology for pain and CNS indications.

TypeBroad incumbent
Description

Janssen markets Risperdal Consta (pioneer risperidone LAI) and Invega Sustenna/Hafyera (paliperidone LAI), the dominant long-acting injectable antipsychotics. Broad incumbent in MedinCell's primary commercial category with established market leadership.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MedinCell

Long-acting injectable pharmaceuticalsmedincell.com

MedinCell is a French clinical- and commercial-stage biopharmaceutical company that licenses its proprietary BEPO long-acting injectable polymer platform to pharmaceutical partners, generating royalties from Teva's UZEDY (risperidone LAI) and co-developing pipeline assets in schizophrenia, pain, contraception, and malaria.

What MedinCell does

MedinCell SA is a clinical- and commercial-stage biopharmaceutical company headquartered near Montpellier, France, that develops long-acting injectable (LAI) drug formulations on its proprietary BEPO technology platform. BEPO uses PEG-PLA diblock and triblock copolymers that form a small, fully bioresorbable subcutaneous or local depot upon contact with aqueous environments; the depot releases the entrapped active pharmaceutical ingredient by diffusion and polymer degradation at therapeutic levels for days, weeks, or months from a single injection, with release kinetics tunable via the hydrophilicity and ratio of the diblock and triblock components. The platform underpins 15 active programs spanning neuroscience, immunology, oncology, endocrinology, infectious diseases, and pain management. The lead commercial product, UZEDY (risperidone LAI, marketed under the SteadyTeq trademark by Teva), received FDA approval in April 2023 for schizophrenia and was expanded in October 2025 to include Bipolar I Disorder, with additional approvals in Canada and South Korea in 2025.

MedinCell operates a licensing- and royalty-driven business model rather than direct commercialization. Its primary commercial partner is Teva Pharmaceuticals, which markets UZEDY in the United States, Canada, and South Korea and is co-developing olanzapine LAI (TEV-749/mdc-TJK), for which both FDA NDA acceptance (February 2026) and EMA MAA acceptance (May 2026) have been secured. The company also has a strategic co-development agreement with AbbVie for next-generation LAIs, a partnership with Arthritis Innovation Corporation for mdc-CWM (intra-articular celecoxib for post-operative pain), and non-dilutive grant funding from the Bill & Melinda Gates Foundation and Unitaid for global health programs targeting malaria (mdc-STM) and contraception (mdc-WWM). FY2026 total income was €24.3 million, with UZEDY royalties contributing €9.3 million (+42% year-over-year, now 38% of total revenue) and the company reporting a net loss of €31.29 million against a year-end cash position of €80.8 million, bolstered by a €48 million private placement completed in March 2026.

The company employs approximately 140 people across more than 25 nationalities, with 73% of staff dedicated to R&D and 91% participating as shareholders. MedinCell is publicly listed on Euronext Paris under the ticker MEDCL, was included in the MSCI World Small Cap Index effective November 24, 2025, and holds ISS ESG Prime Status with a Corporate Rating upgraded from C+ to B in 2025. The board and management team include veterans of Teva, Novartis, Alcon, AbbVie Ventures, and Intra Cellular Therapies, supporting the company's stated "Shift to Growth" strategy of transitioning toward a royalty-driven commercial model.

MedinCell firmographics

Firmographics
Name
MedinCell
Legal name
MedinCell SA
Website
https://medincell.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
MedinCell is a French clinical- and commercial-stage biopharmaceutical company that licenses its proprietary BEPO long-acting injectable polymer platform to pharmaceutical partners, generating royalties from Teva's UZEDY (risperidone LAI) and co-developing pipeline assets in schizophrenia, pain, contraception, and malaria.
Ownership category
akta.pro rank

MedinCell industry classification

Industry
Product category
Long-acting injectable pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Long-acting injectables
  • Bioresorbable polymers
  • Drug delivery systems
  • Biopharmaceutical licensing
  • Sustained-release formulations

Where MedinCell is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices2 records

Markets served

MedinCell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Royalty Income from UZEDY: MedinCell receives mid- to high-single-digit royalties on UZEDY net sales from Teva. UZEDY royalties reached EUR 9.3 million in FY2026, representing 38% of total revenue, up from 22% in FY2025. Teva's net sales of UZEDY reached $215 million in FY2026, up 52.5% year over year.
  2. Commercial Milestone Payments: MedinCell is eligible for up to $105 million in commercial milestone payments upon achievement of annual sales thresholds for UZEDY. Additional $4 million payment upon approval for Olanzapine LAI.
  3. R&D Grants and Non-dilutive Funding: Funding from foundations for global health programs: $19 million grant from Bill & Melinda Gates Foundation for mdc-WWM contraceptive program, up to $6.4 million from Unitaid for malaria program (mdc-STM), with extension grants of up to $6 million. $3 million grant from Gates Foundation for ivermectin-based malaria treatment (mdc-STM).
  4. Co-development and Licensing Agreements: Strategic co-development and licensing partnerships including AbbVie collaboration for next-generation LAI therapies. Revenue from upfront payments, development milestones, and royalties from partnered programs.
  5. Private Placement and Equity Financing: EUR 48 million private placement completed March 2026 through issuance of 2,370,000 new shares at EUR 20.35 per share. EUR 40 million loan agreement with European Investment Bank signed November 2022.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualRoyalty-based revenue model from licensed products

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

MedinCell product offering

Product offering

Core offering

MedinCell develops and licenses its proprietary BEPO® long-acting injectable technology platform, which uses PEG-PLA diblock and triblock copolymers to form a small, fully bioresorbable depot under the skin that delivers active pharmaceutical ingredients at therapeutic levels for days, weeks, or months following a single subcutaneous or local injection. The commercial-stage product UZEDY® (risperidone long-acting injectable) is FDA-approved for schizophrenia and Bipolar I Disorder and is marketed by partner Teva. The company monetizes the technology through royalties, milestone payments, and co-development partnerships with leading pharmaceutical companies and global health foundations.

Product overview

MedinCell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments. The portfolio centers on the proprietary BEPO® technology platform, which enables controlled drug delivery via bioresorbable depots. The commercial-stage product UZEDY® (risperidone LAI) is marketed by Teva for schizophrenia and Bipolar I Disorder. The pipeline includes mdc-TJK (olanzapine LAI, Phase 3 complete, NDA/MAA accepted), mdc-CWM (post-operative pain, Phase 3 complete), mdc-WWM (contraceptive, Phase 1), mdc-STM (malaria, preclinical), and mdc-AbbVie-1 (confidential, partnership with AbbVie). Programs span neuroscience, immunology, oncology, endocrinology, infectious diseases, and pain management. The company has 15 active programs total.

Differentiator

Problem solved

Functional benefit

Brands

  • UZEDY: Monthly and every 2 months subcutaneous risperidone for treatment of schizophrenia and Bipolar I Disorder; FDA-approved long-acting injectable based on BEPO technology, marketed by Teva in the US
  • BEPO
  • SteadyTeq

Products and services

  • UZEDY® (risperidone long-acting injectable) Monthly and every-two-months subcutaneous risperidone long-acting injectable based on BEPO® technology for the treatment of schizophrenia and Bipolar I Disorder in adults. FDA-approved in April 2023 for schizophrenia, with expanded indication for Bipolar I Disorder approved October 2025. Marketed by Teva in the US under the SteadyTeq® license and also approved in Canada (marketed as LONGAVO®) and South Korea in 2025.
  • mdc-TJK (Olanzapine long-acting injectable) Investigational once-monthly subcutaneous long-acting injection of olanzapine for treatment of schizophrenia, in partnership with Teva Pharmaceuticals. Phase 3 complete with SOLARIS trial data showing no PDSS (Postinjection Delirium/Sedation Syndrome) and no required post-injection monitoring, differentiating from existing olanzapine LAIs that carry FDA black box warnings and REMS requirements. NDA accepted by FDA in February 2026 and Marketing Authorization Application accepted by EMA in May 2026.
  • mdc-CWM (intra-articular celecoxib) One-time intra-articular celecoxib sustained-release formulation for post-operative pain relief after total knee replacement surgery, active for up to three months post-surgery. Collaboration with Arthritis Innovation Corporation (AIC) based in Toronto, Canada, which finances and conducts clinical development. Phase 3 results positive, with the goal of reducing opioid dependency.
  • mdc-WWM (6-month subcutaneous contraceptive) Six-month active injectable bioresorbable subcutaneous contraceptive using a non-MPA progestin molecule. Could be the first contraceptive combining 6-month duration, subcutaneous injection, full bio-resorption, and affordability for women in low- and middle-income countries. Funded by up to $19 million grant from the Bill & Melinda Gates Foundation as part of MedinCell's Global Access strategy. Preclinical and Phase 1 activities ongoing.
  • mdc-STM (3-month ivermectin for malaria) Three-month ivermectin long-acting injectable for malaria transmission control. Administered at the beginning of transmission season to eliminate malaria-transmitting mosquitoes. Collaboration with IRD, IRSS, and CIRDES research institutes. Supported by Unitaid (up to $6.4M initial grant plus up to $6M extension) and the Bill & Melinda Gates Foundation ($3M grant). Licensed non-exclusively to the Medicines Patent Pool for distribution via the public sector in low- and middle-income countries.
  • mdc-AbbVie-1 (next-generation long-acting injectable) Confidential next-generation long-acting injectable therapy program developed under strategic co-development and licensing agreement with AbbVie, signed April 2024. The collaboration represents MedinCell's expansion beyond neuroscience into other therapeutic areas; specific indication and molecule details are confidential. Clinical trials are expected to begin in 2027.
  • BEPO® Technology Platform (licensed as SteadyTeq®) Proprietary long-acting injectable technology platform enabling controlled drug delivery at therapeutic levels for several days, weeks, or months following subcutaneous or local injection of a small, fully bioresorbable depot. Composed of PEG-PLA diblock and triblock copolymers that form an in-situ depot millimeters under the skin when exposed to aqueous environment. Licensed to Teva under the SteadyTeq® trademark and used in UZEDY® and TEV-749 olanzapine LAI products. The platform enables tunable release kinetics by adjusting copolymer hydrophilicity and relative ratio.

Quantifiable outcome

  • UZEDY net sales grew 63% from $117M in 2024 to $191M in 2025
  • +5 more outcomes

Companies that use MedinCell

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

MedinCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MedinCell partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • AbbViecoreStrategic or Co-development Partner · 16 April 2024Strategic co-development and licensing agreement to develop next-generation long-acting injectable therapies. First clinical development program with AbbVie has been delayed, with trials now expected to begin in 2027. The collaboration represents MedinCell's expansion beyond neuroscience into other therapeutic areas.
  • Teva PharmaceuticalscoreStrategic or Co-development Partner · 28 April 2023Teva is the primary commercial partner for MedinCell's BEPO technology. Teva markets UZEDY (risperidone LAI) in the US, Canada, and South Korea following FDA approval in April 2023 and subsequent approvals. Teva is also co-developing olanzapine LAI (TEV-749/mdc-TJK) with MedinCell's SteadyTeq technology. Teva reported $191 million in UZEDY net sales in 2025 and $215 million in FY2026. MedinCell receives mid- to high-single-digit royalties on net sales.
  • Medicines Patent PoolsecondaryStrategic or Co-development Partner · 14 September 2022License agreement for malaria transmission-fighting product distribution via public sector in low- and middle-income countries. Part of MedinCell's Global Access strategy to ensure equitable access to health products.
  • UnitaidcoreStrategic or Co-development Partner · 25 March 2020$6.4 million initial grant and up to $6 million extension grant for mdc-STM, a 3-month ivermectin formulation to combat malaria transmission. MedinCell signs license agreement with Medicines Patent Pool for distribution via public sector in LMICs.
  • Arthritis Innovation Corporation (AIC)secondaryStrategic or Co-development Partner · 18 September 2019Collaboration for mdc-CWM, a one-time intra-articular celecoxib formulation for post-operative pain relief after total knee replacement. AIC finances and conducts clinical development activities. Phase 3 results have been positive.
  • Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 7 December 2017Up to $19 million grant for development of mdc-WWM, a 6-month injectable bioresorbable subcutaneous contraceptive. The Global Access strategy aims to ensure widespread availability with affordable pricing in emerging economies. Foundation holds non-exclusive license for non-commercial market in low- and middle-income countries.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

MedinCell competitors and assessment

Company assessment

Others

  • Teva Pharmaceutical Industries: Teva is MedinCell's primary commercialization partner for UZEDY and olanzapine LAI. Teva provides commercial reach and infrastructure; they are not a peer in the technology sense but their commercial performance directly drives MedinCell's royalty stream.
  • PolyPeptide Group: PolyPeptide is a CDMO specializing in peptide-based and sustained-release injectable formulations. Not a direct competitor but adjacent infrastructure provider in the LAI/depot formulation ecosystem that MedinCell operates within.

Direct peers

  • Camurus: Camurus is a Swedish specialty pharma with FluidCrystal technology for long-acting injectable and depot formulations. Markets Buvidal (buprenorphine LAI) for opioid use disorder. Closely comparable as a technology-platform LAI developer partnering with larger pharma.
  • Otsuka Pharmaceutical: Otsuka markets Abilify Maintena and Abilify Asimtufii (aripiprazole LAI) for schizophrenia. Direct competitor to UZEDY/risperidone LAI in the long-acting injectable antipsychotic space and comparable therapeutic-area presence.
  • Alkermes: Alkermes is a leading long-acting injectable technology company developing Vivitrol (naltrexone), Aristada (aripiprazole LAI), and Lybalvi. Directly comparable to MedinCell as a specialty pharma using proprietary depot technology to enable sustained-release injectables for CNS and addiction.
  • Intra-Cellular Therapies: Developed Caplyta (lumateperone) for schizophrenia and bipolar, with a focus on CNS specialty pharma. Acquired by J&J in April 2025 for $14.6B. Comparable business model as a CNS-focused specialty pharma with innovative oral therapeutics for the same patient population.
  • Indivior: Indivior is a specialty pharma focused on addiction treatment with Sublocade (buprenorphine LAI). Comparable as a single-indication LAI specialist that built a commercial-stage franchise around sustained-release depot technology.

Regional players

  • Luye Pharma Group: Luye Pharma developed a risperidone long-acting injectable (Rykindo) approved in the US and operates a microsphere-based LAI platform. Comparable as a global LAI developer; primary geographic focus on China and Asia.

Emerging players

  • Heron Therapeutics: Heron Therapeutics developed sustained-release postoperative pain management products using its Biochronomer polymer technology. Comparable as a specialty pharma using polymer-based LAI/depot technology for pain and CNS indications.

Broad incumbents

  • Johnson & Johnson (Janssen): Janssen markets Risperdal Consta (pioneer risperidone LAI) and Invega Sustenna/Hafyera (paliperidone LAI), the dominant long-acting injectable antipsychotics. Broad incumbent in MedinCell's primary commercial category with established market leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MedinCell social profiles

Digital presence

MedinCell compliance and trust

Trust signal

Compliance1 record

MedinCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MedinCell leadership team

Management profile

Number of profiles

Profiles19 records

MedinCell funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MedinCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedinCell

What does MedinCell do?

MedinCell develops and licenses its proprietary BEPO® long-acting injectable technology platform, which uses PEG-PLA diblock and triblock copolymers to form a small, fully bioresorbable depot under the skin that delivers active pharmaceutical ingredients at therapeutic levels for days, weeks, or months following a single subcutaneous or local injection. The commercial-stage product UZEDY® (risperidone long-acting injectable) is FDA-approved for schizophrenia and Bipolar I Disorder and is marketed by partner Teva. The company monetizes the technology through royalties, milestone payments, and co-development partnerships with leading pharmaceutical companies and global health foundations.

Is MedinCell a public or private company?

MedinCell is a public company. It is classified as public and is currently operating.

When was MedinCell founded?

MedinCell was founded in 2003. It employs 101 to 250 people.

Where is MedinCell based?

MedinCell is headquartered in Montpellier, France, in the Europe region.

How does MedinCell make money?

Five revenue lines are on record. Royalty Income from UZEDY is the primary driver. The others are commercial Milestone Payments, R&D Grants and Non-dilutive Funding, co-development and Licensing Agreements and private Placement and Equity Financing.

Who are MedinCell's main competitors?

Others on record are Teva Pharmaceutical Industries and PolyPeptide Group. Direct peers are Camurus, Otsuka Pharmaceutical, Alkermes, Intra-Cellular Therapies and Indivior. Luye Pharma Group is listed as a regional player. Heron Therapeutics is listed as an emerging player. Johnson & Johnson (Janssen) is listed as a broad incumbent.

Does MedinCell have an API?

No public API is recorded for MedinCell.

What industry is MedinCell in?

MedinCell's product category is Long-acting injectable pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMedinCell (ENXTPA:MEDCL), Why Is The Story Getting More Complicated?MedinCell's stock rebounded 7.89% over the past week but remains down 10% over a year, with a fair value of €35.07 implied by a 19% undervaluation narrative. The company relies on two products, UZEDY and Olanzapine LAI, making it vulnerable to clinical or regulatory setbacks. Future profitability hinges on regulatory approvals, especially for Olanzapine LAI in 2026.Stock TitanMedincell UZEDY Q3 U.S. net sales rise 96% to $85MTeva reported UZEDY U.S. net sales of $85M in Q3 2026, up 96% year-on-year, with total 2026 sales reaching $225M. Teva raised its 2026 revenue outlook to $290-310M, up from $270-290M. Medincell receives royalties and is eligible for up to $105M in milestone payments.YahooIs MedinCell (ENXTPA:MEDCL) Trading Above Fair Value On Sales?MedinCell's shares trade at a P/S of 39.0x, far above the pharmaceuticals industry average of 2.5x and peer group of 4.8x. A fair-value model flags the stock as overvalued, citing losses and uncertain future revenue. The stock's next move depends on whether sales support the current price.Simply Wall StMedinCell (ENXTPA:MEDCL) Financing Reset Puts Its Undervalued Narrative Back In FocusMedinCell secured €41.8 million in non-dilutive bank financing since July 2026, repaying half of its EIB loan and extending maturities to 2031. The stock gained 14.25% over one month and 6.39% year-to-date, though its one-year total shareholder return fell 27.59%. Analysts see a fair value of €35.07 per share, implying 25% undervaluation.Business & FinancialSchizophrenia Market Forecast 2036: Rising Demand, Novel Therapies, And Commercial Potential Delveinsight Teva Pharma, Royalty Pharma, Medincell, Sumitomo Pharma, Otsuka Pharma, Reviva PharmaDelveInsight's schizophrenia market report projects the market to grow from $8 billion in 2025 to a higher value by 2036, with the US leading at $6 billion in 2024. The UK is expected to overtake Germany in the EU4+UK region by 2036, and novel therapies like Teva's Weltruza are anticipated to reshape market dynamics.YahooMedinCell (ENXTPA:MEDCL) Secures €41.8 Million In Non Dilutive FinancingMedinCell secured €41.8 million in non-dilutive financing from European banks and Bpifrance since July 2026. The company partially repaid its €23.2 million EIB loan and extended its maturity to September 2031, while maintaining €84.8 million in cash as of March 31, 2026.FinancialContent Business PageMedincell Announces New Publication Date for Its Half-Year Financial Result (April 1st – September 30, 2026)Medincell rescheduled its half-year financial results for the period April 1–September 30, 2026, from December 8 to December 9, 2026, citing operational reasons. The company also highlighted its BEPO technology and FDA-approved Risperidone LAI (UZEDY) and Olanzapine LAI (WELTRUZA) treatments.Les EchosSchizophrénie : MedinCell impose avec Teva sa technologie à action prolongée aux Etats-UnisMedinCell's partner Teva received FDA approval for Weltruza, an olanzapine subcutaneous injection for schizophrenia, on October 9. Teva plans to launch the product in the US within weeks. The company's CEO called it a historic milestone.FinancialContent Business PageMedincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million LoanMedincell announced an additional €13.8 million in non-dilutive financing from European banks and Bpifrance, bringing total non-dilutive financing since July 2026 to €41.8 million. The company repaid 50% of its EIB loan in July 2026, and extended its debt maturity to September 2031.The future of tradingMedincell secures EUR 13.8 million non-dilutive loan from European banks, BpifranceMedincell secured an additional EUR 13.8 million non-dilutive loan from European banks and Bpifrance. Total non-dilutive financing raised since July 2026 increased to EUR 41.8 million, with cash and equivalents at EUR 84.8 million as of March 31, 2026.